Increased PD-L1 Expression in HER2-Positive Breast Cancer without Pathologic Complete Response to Neoadjuvant Therapy

被引：0
|
作者：
Yang, Fei [1 ]
Song, Juhee [2 ]
Mino, Barbara [1 ]
Parra, Edwin R. [1 ]
Sahin, Aysegul [2 ]
Wistuba, Ignacio [2 ]
Litton, Jennifer [2 ]
Mittendorf, Elizabeth [2 ]
Wu, Yun
机构：
[1] UT MD Anderson Canc Ctr, Houston, TX USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
LABORATORY INVESTIGATION | 2018年 / 98卷
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
321
引用
收藏
页码：114 / 114
页数：1
相关论文
共 50 条
  • [1] Increased PD-L1 Expression in HER2-Positive Breast Cancer without Pathologic Complete Response to Neoadjuvant Therapy
    Yang, Fei
    Song, Juhee
    Mino, Barbara
    Parra, Edwin R.
    Sahin, Aysegul
    Wistuba, Ignacio
    Litton, Jennifer
    Mittendorf, Elizabeth
    Wu, Yun
    MODERN PATHOLOGY, 2018, 31 : 114 - 114
  • [2] Clinicopathological values of PD-L1 expression in HER2-positive breast cancer
    Sasagu Kurozumi
    Kenichi Inoue
    Hiroshi Matsumoto
    Takaaki Fujii
    Jun Horiguchi
    Tetsunari Oyama
    Masafumi Kurosumi
    Ken Shirabe
    Scientific Reports, 9
  • [3] Clinicopathological values of PD-L1 expression in HER2-positive breast cancer
    Kurozumi, Sasagu
    Inoue, Kenichi
    Matsumoto, Hiroshi
    Fujii, Takaaki
    Horiguchi, Jun
    Oyama, Tetsunari
    Kurosumi, Masafumi
    Shirabe, Ken
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [4] Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy
    Takeo Fujii
    Takahiro Kogawa
    Jimin Wu
    Aysegul A Sahin
    Dian D Liu
    Mariana Chavez-MacGregor
    Sharon H Giordano
    Akshara Raghavendra
    Rushmy K Murthy
    Debu Tripathy
    Yu Shen
    Jose-Miguel Yamal
    Naoto T Ueno
    British Journal of Cancer, 2017, 116 : 509 - 514
  • [5] Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy
    Fujii, Takeo
    Kogawa, Takahiro
    Wu, Jimin
    Sahin, Aysegul A.
    Liu, Dian D.
    Chavez-MacGregor, Mariana
    Giordano, Sharon H.
    Raghavendra, Akshara
    Murthy, Rushmy K.
    Tripathy, Debu
    Shen, Yu
    Yamal, Jose-Miguel
    Ueno, Naoto T.
    BRITISH JOURNAL OF CANCER, 2017, 116 (04) : 509 - 514
  • [6] Tumor infiltlating lymphocytes and PD-L1 expression in HER2-positive breast cancer treated with neoadjuvant chemothepary
    Tokunaga, Eriko
    Taguchi, Kenichi
    Nami, Yamashita
    Morita, Masaru
    Ishida, Mayumi
    CANCER SCIENCE, 2018, 109 : 125 - 125
  • [7] PD-1 and PD-L1 Expression in HER2-Positive Breast Carcinomas
    Ubago, Julianne M.
    Larson, Alexandra
    Eghtesad, Mansooreh
    Blanco, Luis Z.
    Pincus, Jennifer
    Siziopikou, Kalliopi P.
    MODERN PATHOLOGY, 2017, 30 : 75A - 75A
  • [8] PD-1 and PD-L1 Expression in HER2-Positive Breast Carcinomas
    Ubago, Julianne M.
    Larson, Alexandra
    Eghtesad, Mansooreh
    Blanco, Luis Z.
    Pincus, Jennifer
    Siziopikou, Kalliopi P.
    LABORATORY INVESTIGATION, 2017, 97 : 75A - 75A
  • [9] Evaluation of Immune Reaction and PD-L1 Expression Using Multiplex Immunohistochemistry in HER2-Positive Breast Cancer: The Association With Response to Anti-HER2 Neoadjuvant Therapy
    Hou, Yanjun
    Nitta, Hiroaki
    Wei, Lai
    Banks, Peter M.
    Parwani, Anil V.
    Li, Zaibo
    CLINICAL BREAST CANCER, 2018, 18 (02) : E237 - E244
  • [10] Comment on 'Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy'
    Altundag, Kadri
    BRITISH JOURNAL OF CANCER, 2017, 116 (08) : e10 - e10
12345